This medicinal product is for diagnostic use.
Ultravist-240, -300, -370:
–Angiography, angiocardiography, digital subtraction angiography
–Contrast enhancement in computerised tomography
–Urography
–Visualization of body cavities
(Exception: myelography, ventriculography, cisternography)
Ultravist-300/-370:
Used in adult women for contrast-enhanced mammography to assess and detect known or suspicious lesions of the breast,
–in addition to mammography (with or without ultrasound) or
–as an alternative to magnetic resonance imaging (MRI) if MRI is contraindicated or not available.
NOVACTAM is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.
Skin and Skin Structure Infections caused by beta‑lactamase producing strains of Staphylococcus aureus, Escherichia coli,* Klebsiella spp.* (including K. pneumoniae*), Proteus mirabilis,* Bacteroides fragilis,* Enterobacter spp.,* and Acinetobacter calcoaceticus.*
Intra‑Abdominal Infections caused by beta‑lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.*
Gynecological Infections caused by beta‑lactamase producing strains of Escherichia coli,* and Bacteroides spp.* (including B. fragilis*).
* Efficacy for this organism in this organ system was studied in fewer than 10 infections.
While NOVACTAM is indicated only for the conditions listed above, infections caused by ampicillin‑susceptible organisms are also amenable to treatment with NOVACTAM due to its ampicillin content. Therefore, mixed infections caused by ampicillin‑susceptible organisms and beta‑lactamase producing organisms susceptible to NOVACTAM should not require the addition of another antibacterial.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to NOVACTAM.
Intended for the following indications:
·Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.
·Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Efanesoctocog Alfa can be used for all age groups.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Efanesoctocog Alfa can be used for all age groups.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Efanesoctocog Alfa can be used for all age groups.
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Efanesoctocog Alfa can be used for all age groups.
